This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
Scientific Reports Open Access 01 December 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270, 470–475 (1995).
Blaese, R.M. et al. T lymphocyte–directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475–480 (1995).
Kohn, D.B. et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1, 1017–1023 (1995).
Hoogerbrugge, P.M. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179–183 (1996).
Onodera, M. et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91, 30–36 (1998).
Ochs, H.D. et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood 80, 1163–1171 (1992).
Parkman, R., Gelfand, E.W., Rosen, F.S., Sanderson, A. & Hirschhorn, R. Severe combined immunodeficiency and adenosine deaminase deficiency. N. Engl. J. Med. 292, 714–719 (1975).
Hirschhorn, R., Roegner, M.V., Kuritsky, L. & Rosen, F.S. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J. Clin. Invest. 68, 1387–1393 (1981).
Kohn, D.B. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Med. 4, 775–780 (1998).
Arredondo, V.F., Santisteban, I., Daniels, S., Toutain, S. & Hershfield, M.S. Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet 63, 1049–1059 (1998).
Bordignon, C. et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum. Gene Ther. 4, 513–520 (1993).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Aiuti, A., Vai, S., Mortellaro, A. et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8, 423–425 (2002). https://doi.org/10.1038/nm0502-423
Issue Date:
DOI: https://doi.org/10.1038/nm0502-423
This article is cited by
-
Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
Scientific Reports (2021)
-
Hematopoietic Stem Cell Mobilization: Current Collection Approaches, Stem Cell Heterogeneity, and a Proposed New Method for Stem Cell Transplant Conditioning
Stem Cell Reviews and Reports (2021)
-
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Nature Reviews Drug Discovery (2019)
-
Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry
Gene Therapy (2017)
-
Gene Therapy for SCID
Current Pediatrics Reports (2015)